Timing of initiation of antiretroviral therapy and adverse pregnancy outcomes: a systematic review and meta-analysis

The Lancet HIV

Volumn 4, Issue 1, 2017, Pages e21-e30

  Uthman, Olalekan A ^a,b,c   Nachega, Jean B ^c,d,e   Anderson, Jean ^f   Kanters, Steve ^g,h   Mills, Edward J ^h   Renaud, Françoise ⁱ   Essajee, Shaffiq ⁱ   Doherty, Meg C ^f,i   Mofenson, Lynne M ^j  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b KAROLINSKA INSTITUTE   (Sweden)

^c STELLENBOSCH UNIVERSITY   (South Africa)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^h Department of Health Analytics   (Canada)

ⁱ WORLD HEALTH ORGANIZATION   (Switzerland)

^j ELIZABETH GLASER PEDIATRIC AIDS FOUNDATION   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; CD4 LYMPHOCYTE COUNT; CONGENITAL MALFORMATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOW BIRTH WEIGHT; META ANALYSIS (TOPIC); NEWBORN MORTALITY; PREGNANCY OUTCOME; PREMATURITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMALL FOR DATE INFANT; STILLBIRTH; SYSTEMATIC REVIEW; TIME TO PREGNANCY; VERY LOW BIRTH WEIGHT; ADVERSE EFFECTS; BIRTH WEIGHT; DRUG ADMINISTRATION; DRUG EFFECTS; FEMALE; HIV INFECTIONS; INFANT; INTERNATIONAL COOPERATION; META ANALYSIS; MOTHER; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVENTION AND CONTROL; PROSPECTIVE STUDY; SOCIOECONOMICS; TRANSMISSION; VERTICAL TRANSMISSION; VIROLOGY;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIRTH WEIGHT; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HUMANS; INFANT; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; INTERNATIONAL COOPERATION; MOTHERS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY OUTCOME; PROSPECTIVE STUDIES; SOCIOECONOMIC FACTORS;

EID: 85006368806     PISSN: None     EISSN: 23523018     Source Type: Journal    
DOI: 10.1016/S2352-3018(16)30195-3     Document Type: Article

References (33)

1. 1 WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection recommendations for a public health approach. http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf (accessed Sept 26, 2015).
2. 2 TEMPRANO ANRS 12136 Study Group. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med 373 (2015), 808–822.
3. 3 INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 373 (2015), 795–807.
4. 4 WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection—recommendations for a public health approach. http://www.who.int/hiv/pub/arv/arv-2016/en/ (accessed June 27, 2016).
5. 5 Townsend, CL, Byrne, L, Cortina-Borja, M, et al. Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000–2011. AIDS 28 (2014), 1049–1057.
6. 6 Mandelbrot L, Tubiana R, Le Chenadec J, et al. No perinatal transmission of HIV-1 in women efficiently treated since conception. 22nd Conference on Retroviruses and Opportunistic Infections (CROI); Seattle, WA, USA; Feb 23–26, 2015; abstr 867.
7. 7 Mofenson, LM, Antiretroviral therapy and adverse pregnancy outcome: the elephant in the room?. J Infect Dis 213 (2016), 1051–1054.
8. 8 Ades, V, Mwesigwa, J, Natureeba, P, et al. Neonatal mortality in HIV-exposed infants born to women receiving combination antiretroviral therapy in rural Uganda. J Trop Pediatr 59 (2013), 441–446.
9. 9 Chen, JY, Ribaudo, HJ, Souda, S, et al. Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana. J Infect Dis 206 (2012), 1695–1705.
10. 10 Short, CE, Douglas, M, Smith, JH, Taylor, GP, Preterm delivery risk in women initiating antiretroviral therapy to prevent HIV mother-to-child transmission. HIV Med 15 (2014), 233–238.
11. 11 Sibiude, J, Warszawski, J, Tubiana, R, et al. Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy: role of the ritonavir boost?. Clin Infect Dis 54 (2012), 1348–1360.
12. 12 Ekouevi, DK, Coffie, PA, Becquet, R, et al. Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Côte d'Ivoire. AIDS 22 (2008), 1815–1820.
13. 13 Grosch-Woerner, I, Puch, K, Maier, RF, et al. Increased rate of prematurity associated with antenatal antiretroviral therapy in a German/Austrian cohort of HIV-1-infected women. HIV Med 9 (2008), 6–13.
14. 14 Powis, KM, Kitch, D, Ogwu, A, et al. Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy. J Infect Dis 204 (2011), 506–514.
15. 15 Ravizza, M, Martinelli, P, Bucceri, A, et al. Treatment with protease inhibitors and coinfection with hepatitis C virus are independent predictors of preterm delivery in HIV-infected pregnant women. J Infect Dis 195 (2007), 913–914.
16. 16 Li, N, Sando, MM, Spiegelman, D, et al. Antiretroviral therapy in relation to birth outcomes among HIV-infected women: a cohort study. J Infect Dis 213 (2016), 1057–1064.
17. 17 Guyatt, GH, Oxman, AD, Vist, GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336 (2008), 924–926.
18. 18 Higgins, JP, Thompson, SG, Deeks, JJ, Altman, DG, Measuring inconsistency in meta-analyses. BMJ 327 (2003), 557–560.
19. 19 Egger, M, Davey Smith, G, Schneider, M, Minder, C, Bias in meta-analysis detected by a simple, graphical test. BMJ 315 (1997), 629–634.
20. 20 Liberati, A, Altman, DG, Tetzlaff, J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ, 339, 2009, b2700.
21. 21 Thorne, C, Rudin, C, Newell, M-L, et al. Combination antiretroviral therapy and duration of pregnancy. AIDS 14 (2000), 2913–2920.
22. 22 Patel, D, Thorne, C, Fiore, S, Newell, ML, Does highly active antiretroviral therapy increase the risk of congenital abnormalities in HIV-infected women?. J Acquir Immune Defic Syndr 40 (2005), 116–118.
23. 23 Martin, F, Taylor, GP, Increased rates of preterm delivery are associated with the initiation of highly active antiretrovial therapy during pregnancy: a single-center cohort study. J Infect Dis 196 (2007), 558–561.
24. 24 Machado, ES, Hofer, CB, Costa, TT, et al. Pregnancy outcome in women infected with HIV-1 receiving combination antiretroviral therapy before versus after conception. Sex Transm Infect 85 (2009), 82–87.
25. 25 Aniji, CD, Towobola, OA, Hoque, ME, Mashamba, TJ, Monokoane, S, Original article: Impact of antiretroviral therapy on pregnancy outcomes. S Afr J HIV Med 14 (2013), 176–178.
26. 26 Dale, H, Chigiga, J, Manavi, K, Does initiation of highly active antiretroviral therapy (HAART) before pregnancy increase risk of adverse outcomes: miscarriage, prematurity, stillbirth?. HIV Med 14 (2013), 5–6.
27. 27 Mandelbrot, L, Tubiana, R, Le Chenadec, J, et al. No perinatal HIV-1 transmission from women with effective antiretroviral therapy starting before conception. Clin Infect Dis 61 (2015), 1715–1725.
28. 28 Zash, R, Souda, S, Chen, JY, et al. Reassuring birth outcomes with tenofovir/emtricitabine/efavirenz used for prevention of mother-to-child transmission of HIV in Botswana. J Acquir Immune Defic Syndr 71 (2016), 428–436.
29. 29 Brocklehurst, P, French, R, The association between maternal HIV infection and perinatal outcome: a systematic review of the literature and meta-analysis. Br J Obstet Gynaecol 105 (1998), 836–848.
30. 30 Kourtis, AP, Schmid, CH, Jamieson, DJ, Lau, J, Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis. AIDS 21 (2007), 607–615.
31. 31 Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry interim report for 1 Jan 1989 through 31 January 2015, 2015, Registry Coordinating Center, Wilmington, NC.
32. 32 Thorne, C, Townsend, CL, A new piece in the puzzle of antiretroviral therapy in pregnancy and preterm delivery risk. Clin Infect Dis 54 (2012), 1361–1363.
33. 33 Powis, KM, Shapiro, RL, Protease inhibitors and adverse birth outcomes: is progesterone the missing piece to the puzzle?. J Infect Dis 211 (2015), 4–7.